INTRODUCING
The most advanced human-derived HBOC platform in development for hemorrhagic shock and donor organ transplants.
When blood is not an option.
1.9Million
Die per Year from Blood Loss
Trauma is the leading cause of death for young adults in both military and civilian populations. Over 30% of trauma patients die from hemorrhagic shock and 50% of these deaths occur during the pre-hospital period.
It’s about time. A hemoglobin-based oxygen carrier has been sought for time-critical trauma victims and pre-transplant donor organ support for decades.
In emergencies, before transport to the hospital, blood is rarely an option but oxygenation of vital organs may be critical. Hemorrhage can also be life-threatening in patients who are unable to receive a blood transfusion. OxyBridge™ may be a bridge to transfusion or even an alternative. Stockpiles for disaster emergencies and Department of War applications for combat casualty care are envisioned.
VirTech Bio has a research partnership with a European organ perfusion device manufacturer. Use of OxyBridge™ in such a device allows organs to be warmed and oxygenated prior to transplantation and studies show improved outcomes. When used ex vivo in an organ perfusion device, OxyBridge will be regulated as a device as well.
OxyBridge™ addresses FDA’s HBOC toxicity concern: ultra-polymer design prevents blood pressure increase
No costly factory to be built. Designed for manufacturing by CMO with CMC expertise
Lower COP and higher viscosity – similar to blood to limit fluid shifts and maintain capillary patency
First indication can be pre-transplant organ perfusion – ex vivo device has lower regulatory hurdles
COL(R) Hack served as Senior Medical Advisor to the Principal Assistant, Research and Technology, US Army Medical Research and Materiel Command (USAMRMC) from 2014 to 2015, where he coordinated Brain Health research.
Dallas.Hack@VirTechbio.com
Matias Vidal
Co-Founder & Executive Chairman
W. Richard Light, PhD
Chief Scientific Officer
Martha Farmer, PhD
Executive VP Board Member
Shawn Bengtson, RQAP-GLP
Quality Assurance Advisor
Virginia Rentko, VMD
Veterinary Advisor
Jerry Holmberg PhD
Scientific Advisor
Dr. Aryeh Shander, MD, FCCM
Scientific Advisor
Dr. Kenneth Burhop, PhD
Scientific Advisor
The US Department of War has made an oxygen-carrying resuscitation solution a top priority to address field emergencies where a blood transfusion is simply not an option. VirTech Bio has been awarded $12.15M in non-dilutive funding, every award of it on the public record:
| Award | Amount | Year | Public record |
|---|---|---|---|
| NIH (NIDDK) — SBIR Phase I | $238,970 | 2016 | sbir.gov |
| SOCOM — SBIR Phase I | $148,088 | 2017 | sbir.gov |
| SOCOM — SBIR Phase II | $1,752,422 | 2018 | sbir.gov |
| USAMRDC via MTEC | $10,013,248 | 2019 | mtec-sc.org |
This non-dilutive funding effectively leverages the $6.7M in equity funding thus far invested. The awarded funds cover most of the R&D, the cost of cGMP manufacture of OxyBridge™, and the planned Phase 1 clinical study. OxyBridge™ is the most advanced human-derived HBOC platform currently in development for hemorrhagic shock and donor organ transplantation. The Department of War investment has helped establish VirTech Bio as the leader in the field of hemoglobin oxygen carrier solutions. Please contact us for additional information on our next round of funding: info@virtechbio.com
